Login to Your Account

Zealand Pharma Seeking $126M in Danish IPO

By Cormac Sheridan

Thursday, November 4, 2010
Aiming to capitalize on the flood of Phase III trial data on lixisenatide that has already started to flow, Zealand Pharma A/S is launching an initial public offering (IPO) on the Copenhagen Stock Exchange that could gross $126.1 million (DKK 671.3 million), excluding any overallotments.(BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription